Scinai Immunotherapeutics Eyes Pincell srl Acquisition

TL;DR

Scinai looking to buy Pincell srl and its monoclonal antibody PC111.

AI Summary

Scinai Immunotherapeutics Ltd. announced on September 22, 2025, that it is anticipating the signing of an option agreement to acquire Pincell srl, an Italian biotech company. Pincell srl owns PC111, a monoclonal antibody currently in development for the treatment of certain conditions.

Why It Matters

This potential acquisition could expand Scinai's pipeline with a new monoclonal antibody, potentially impacting its future therapeutic offerings and market position.

Risk Assessment

Risk Level: medium — The filing indicates an anticipated option agreement, meaning the acquisition is not yet finalized and is subject to further negotiation and conditions.

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Registrant
• Pincell srl (company) — Target company for acquisition
• PC111 (drug_candidate) — Monoclonal antibody being developed by Pincell srl

FAQ

From the Filing

0001213900-25-089839.txt : 20250922 0001213900-25-089839.hdr.sgml : 20250922 20250922082704 ACCESSION NUMBER: 0001213900-25-089839 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250922 FILED AS OF DATE: 20250922 DATE AS OF CHANGE: 20250922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 251328514 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0258206-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ As previously announced by Scinai Immunotherapeutics Ltd. (the “Company”), in anticipation of the signing of the option agreement for the acquisition of the Italian biotech company Pincell srl, the owner of PC111, a monoclonal antibody in development for the treatment of pemphigus vulgaris, Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), the parties jointly prepared and submitted a grant application by the Company’s wholly owned Polish subsidiary, seeking Euro 12 million of non-dilutive funding to support the next stage of development of PC111. To facilitate the submission of the application, Pincell exclusively licensed PC111 to the subsidiary. The grant application was submitted under the European Funds for a Modern Economy (FENG) program in Poland. On September 18, 2025, the Company was notified by the National Center for Research and Development in Poland that the grant application was not selected for funding. Under the applicable procedures, this notification represents an interim decision that becomes final only if no appeal is filed within 14 days of receipt or if an appeal, once filed, is ultimately rejected. The Company intends to file an appeal, which is expected to be reviewed within approximately one month after submission, with a final determination anticipated before the end of 2025. The Company believes that certain aspects of the proposed project were misconstrued or misanalyzed in the initial review, and the appeal will focus on addressing these issues. There can be no assurance, however, that the appeal will be successful or that the grant will ultimately be awarded. This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Warning Concerning Forward-Looking Statements This Report contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These for